Trimega Laboratories Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Trimega Laboratories Limited - overview
Established
2005
Location
Manchester, England, UK
Primary Industry
Biotechnology
About
Trimega Laboratories Limited is a UK-based company specializing in advanced technological solutions that enhance operational efficiency across various sectors, including finance, healthcare, and logistics. Trimega Laboratories Limited, founded in 2005 and headquartered in Manchester, UK, focuses on providing software solutions designed to optimize business processes. The company underwent a pivotal acquisition by Ingemino, a portfolio company of CBPE Capital, in February 2012, which solidified its market presence. Details regarding the founder's previous ventures are not available.
Trimega Labs specializes in advanced technological solutions aimed at optimizing operational efficiency across various sectors. The company’s core product offerings include a suite of software tools designed for data analytics, process automation, and integrated communications systems. These tools function to streamline workflows, enhance decision-making capabilities, and improve overall productivity for businesses. Trimega Labs serves a diverse client base of mid-sized enterprises and large corporations in industries such as finance, healthcare, and logistics, with primary markets in Europe and North America.
The flagship offerings have been well-received, showcasing robust functionality and user-friendly interfaces. In the most recent year, Trimega Laboratories Limited reported a revenue of USD 6. 94 mn and an EBITDA of USD 1. 56 mn.
The company generates revenue through subscription models and direct sales of its software products, engaging clients in a B2B framework that ensures a steady revenue stream through annual contracts. Trimega Laboratories Limited intends to leverage recent funding to enhance its product offerings and expand into new markets. The company is designing new software solutions aimed at further optimizing operational efficiencies, with anticipated launches in the upcoming fiscal year. Additionally, Trimega Labs plans to target expansion into emerging markets in Asia and South America within the next two years.
The acquisition by Ingemino in February 2012 will support these initiatives by providing the necessary capital for development and market entry.
Current Investors
Ingemino
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.trimegalabs.co.uk
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Trimega Laboratories Limited - financials
| Fiscal Year Ended | Jan 31, 2007 | Jan 31, 2008 | Jan 31, 2009 | Jan 31, 2010 | Jan 31, 2011 |
|---|---|---|---|---|---|
| Revenue (USD) | 146,709 | 376,490 | - | - | - |
| % Revenue Growth (YoY) | - | 156.6% | - | - | - |
| EBITDA (USD) | (98,304) | (15,276) | - | - | - |
| Operating Income (USD) | (98,315) | (15,598) | - | - | - |
| Operating Margin | (67.0%) | (4.1%) | - | - | - |
| % EBITDA Margin | (67.0%) | (4.1%) | - | - | - |
| NET Income (USD) | (101,504) | (29,959) | - | - | - |
| % Net Margin | (69.2%) | (8.0%) | - | - | - |
Trimega Laboratories Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Trimega Laboratories Limited | - |
Displaying 1 - 1 of 1
Trimega Laboratories Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.